Study of VX-770 and Rifampin in Healthy Male Subjects

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

The objectives of this study are to evaluate the effects of multiple doses of rifampin on the single-dose pharmacokinetics of VX 770.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vertex Pharmaceuticals Incorporated
• Treatments: Rifampin

Criteria

Inclusion Criteria:

• Subject must be male and between 18 and 55 years of age

• Subject must have a body mass index (BMI) from 18 to 30 kg/m2

Exclusion Criteria:

• History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk in administering study drug to the subject

• Subjects who have active tuberculosis, human immunodeficiency virus, hepatitis C, or active hepatitis B